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Conventional and well-established guidelines for the ethical conduct of clinical research are necessary but not
sufficient for addressing research dilemmas related to public health research. There is a particular need for a public
health ethics framework when, in the face of an epidemic, research is urgently needed to promote the common
good. While there is limited experience in the use of a public health ethics framework, the value and potential of
such an approach is increasingly being appreciated. Here we use two examples of adolescent women as potential
candidates for participation in microbicide trials to illustrate how ethical decisions for public health research can
be enhanced by drawing on both traditional research ethics guidance, and the emerging framework for public
health ethics.
Introduction
Globally, one quarter of all HIV infections occur between
the ages of 15–24 and more than half of new infections
occur in people under 25 years (Macqueen and Karim,
2007). In 2004, there were an estimated 10.3 million
people aged 15–24 with HIV infection worldwide, and
an estimated 7000 new infections a day (Macqueen and
Karim, 2007). The majority of these new infections are
heterosexually acquired and in sub-Saharan Africa. In
this region, HIV infection is about three-fold higher in
young women compared to young men, and women are
infected about 5–7 years earlier than men. Indeed the
HIV epidemic in much of sub-Saharan Africa, especially
southern Africa, is fuelled by high HIV incidence rates in
young women under the age of 20 years. Several studies
report that the HIV infection rate in teenage girls is 3–
6 times that of boys in the same age group (Pettifor
et al., 2005; Shisana et al., 2005). Therefore, reducing
HIV infection in young girls under 18 years of age is
critically important for altering the epidemic trajectories
in this region, and for directly benefiting young women.
This is undoubtedly a priority public health imperative.
Current methods for HIV prevention—abstinence,
behaviour change, condom use and medical male
circumcision—are likely to be of limited benefit for
women especially in settings where gender power
disparities contribute to excess HIV infection rates in
women. The use of intravaginal microbicide gels and
vaccines are examples of biomedical interventions under
development that could offer some women some auton-
omy in reducing their vulnerability to HIV infection.
Some indication of the potential public health impact of
a 60 per cent efficacious microbicide can be gleaned from
mathematical modelling data predicting that even if used
by a small proportion of women in high HIV prevalence
countries in half their sexual encounters, where condoms
are not used, then 2.5 million HIV infections could be
averted over 3 years (International Partnership for Mi-
crobicides, 2005). The inclusion of sexually active, HIV
uninfected adolescent women (14–17 years of age) in
HIV prevention efficacy trials will enable them to benefit
immediately from successful trials as opposed to several
years’ delay for post-licensure testing and labelling for
use in adolescent women.
Traditional drug development clinical trials start with
Phase I safety testing, dose finding and pharmacokinetic
studies in 10–20 normal subjects, then proceed to Phase II
trials of about 50–80 persons with the disease where fur-
ther dosing and administration data are obtained and a
decision made on whether to proceed with larger studies.
Phase III trials are then undertaken to establish effective-
ness (depending on anticipated efficacy these could in-
volve several hundred to several thousand participants).
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In contrast microbicide trials start with expanded
Phase I trials of about 40–80 women at various levels
of risk of HIV infection and then proceed to Phase III
trials of several thousands of at-risk women to estab-
lish effectiveness. In the absence of a correlate of pro-
tection, HIV testing remains the best marker of both
safety and efficacy. As the microbicide product pipeline
increases, tough decisions need to be taken about se-
lection of products to test in expensive Phase III trial
designs. As we have learnt from the microbicide trials
conducted to date, the current expanded Phase I test-
ing strategies are insufficient to establish product safety
or predict efficacy. Intermediate-sized trials (Phase IIb
using several hundred randomized patients) have thus
been used to establish safety and efficacy in an at risk
population where incidence rates are sufficiently high
and such studies could generate a more appropriate sig-
nal to proceed to expensive Phase III studies. With the
shift to anti-retroviral-based products a more traditional
drug development pathway is starting to emerge—that is
with no intervening Phase IIb studies.
To date, including recently terminated and ongoing
microbicide effectiveness (Phase III) trials, over 22,000
women have been enrolled in numerous safety and ef-
ficacy trials. By mid-2006, five candidate microbicides
were being tested for efficacy (Phase III trials) to pre-
vent HIV infection at more than 35 clinical sites in
17 countries. More than half a dozen other products
are being assessed in early safety (Phase I) and expanded
safety (Phase IIb) trials (Alliance for Microbicide Devel-
opment, 2008). To date only the Carraguard trial (Skoler-
Karpoff et al., 2008) enrolled 16- and 17-year-old women.
Given the public health imperative for enhancing pro-
tection against infection in young women and the need
for data on the safety and effectiveness of microbicides
in adolescents as a potentially very effective future public
health tool, we contend that it may amount to public
health negligence not to include women under the age of
18 years in Phase III trials
The recent early closure of several microbicide and
vaccine trials illustrates that consideration of safety is not
a trivial issue when testing experimental products. Tra-
ditional ethical considerations of autonomous decision-
making and protection of vulnerable populations are of
great social value. On the other hand, where the public
health imperatives are of the magnitude being experi-
enced by young women in sub-Saharan Africa, it is nec-
essary to consider newer approaches more focused on
public health and the common good that could assist in
moving forward.
It could be argued that valid concerns regarding pro-
tection of vulnerable minors are perhaps being overem-
phasised and insufficient attention is being paid to the
fact that adolescents are likely to benefit most from an
efficacious microbicide, and that a very important so-
cial good would be served by establishing an effective
and safe microbicide for use by young women. Moral
and judgemental positions on sexual activity in young
women (including outside of marriage), concerns about
cognitive ability to provide first-person consent, ability
to adhere to complex trial procedures, potential risk to
immature genital tracts and safety concerns relating to
exposure to experimental drugs, all of which have been
cited as reasons for not enrolling adolescent women in
microbicide trials, despite the elusive factual basis for all
of these concerns, are blocking progress. These concerns
need to be dealt with to improve the feasibility of ac-
cruing cohorts of adolescents, the ability to retain these
cohorts and to obtain adherence to study procedures such
that the power and scientific integrity of the trial is not
compromised
There is potential for risk of HIV infection in all trials
and while steps are taken to minimize this (education
about use of condoms and avoidance of multiple part-
ners), risk cannot be eliminated in the absence of a proxy
correlate of protection. Indeed it is in clinical trials inclu-
sive of at-risk populations that have been most predictive
of harm or potential harm which earlier safety studies in
no, or low, risk populations did not identify. Early micro-
bicide trials of first- and second-generation microbicides
were less specifically HIV protective compared to new
generation microbicides that are anti-retroviral based.
At this point in time HIV testing is both a safety and an
efficacy marker and, given the topical application of mi-
crobicides safety assessments that include genital exami-
nations are essential. By definition microbicide trials only
include women who are sexually active. HIV testing for
safety and efficacy monitoring with ARV-based products
usually involves monthly HIV testing. Safety monitor-
ing using laboratory markers, such as tests of renal and
liver function, and pelvic examinations, is undertaken
less frequently—in some instances once in 3 months.
The comprehension of information provided during the
process of obtaining consent is even more critical in the
conduct of trials that include adolescents and it is neces-
sary to ensure that there is sufficient cognitive ability to
consent, with comprehension assessed prior to initiation
of study procedures and on an ongoing basis.
Cases for Consideration
We shall consider here why it is important for ado-
lescents, such as the two in the case studies below, to
be considered for inclusion in Phase IIb or Phase III
microbicide trials, concentrating on the HIV risk that is
relevant for these women.
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Case 1
A 16-year-old sexually active girl wishes to participate in
a microbicide study. She is not able to give legal consent as
she is a minor but she does not want her parents to know
that she is participating.
Case 2
A 16-year-old sexually active girl wishes to participate in a
microbicide study. She is not able to give her legal consent
as she is a minor. She is unaware of who her father is as
she has been raised by her mother. Her mother has recently
died from AIDS and she is the head of the household and
taking care of her siblings.
These two case studies focus on whether adoles-
cents can give valid consent for their participation in
a clinical trial and on whether good arguments, based
on public health considerations, can be provided for
their inclusion even if conventional criteria for in-
formed consent cannot be fully met. One of the ado-
lescents we discuss has parents, whom she does not
want to have knowledge of her participation, and the
other is the ‘head of the household’, so already fulfill-
ing an ‘adult’ role. Using the conventional approach to
research ethics, these young women could not be in-
cluded in microbicide trials without parental or guardian
consent.
We shall argue that conventional ethical guidelines
are inadequate for the ethical dilemmas that must be
faced when the common good is at stake in a pandemic
that is costing millions of lives, and that where poten-
tially effective preventive measures must be researched
there is scope for inclusion of a public health ethics
approach that could provide justification for including
adolescents in trials with major public health benefits
for their age group. We note that throughout this dis-
cussion, we are referring to adolescent participation in
Phase IIb/III Microbicide trials. The three prerequisites
for enrolment in such a trial are a negative HIV test, no
desire or intention to become pregnant during the trial,
adherence to study procedures including product use,
monthly HIV and pregnancy testing and several pelvic
examinations.
An Outline of a Public Health Ethics
Approach
A public health ethics framework for considering ethical
issues is one that allows for consideration of the common
good in addition to individual choice and rights. While
there is as no coherent framework for a public health
ethics approach that has been accepted or tested, several
authors have offered contributions to how we should
think about public health care dilemmas.
Roberts and Reich have noted that when making pub-
lic health decisions, one of the most difficult issues is the
need to balance what is considered to be best for the pop-
ulation while retaining protection of individuals (Roberts
and Reich, 2002). In their review they describe how
ethical arguments in public health can be grouped into
three main categories, each representing a major theme
in contemporary public health discourse: utilitarianism,
liberalism and communitarianism. They note that while
utilitarianism is highly influential in public health
decision-making, liberalism also has considerable force
as evidenced in the approach to patients who are HIV
positive and that the communitarian perspective, with
its focus on creating a good society in which individuals
within that society exhibit virtues appropriate to that
society, also offers ethical guidance (Roberts and Reich,
2002).
Public health ethics debates embrace arguments across
these philosophical domains each of which may domi-
nate in specific situations, but what is important is that
there should be an explicit discussion of the issues and
well-constructed arguments that facilitate movement to-
wards a coherent position.
Several operational frameworks and principles have
been offered for the analysis of ethical issues in public
health practice. Nancy Kass (2001) has suggested that
six primary questions should be addressed in relation
to the ethical dimensions of any proposed public health
program:
• What are the public health goals of the proposed pro-
gram?
• How effective is the program in achieving its stated
goals?
• What are the known or potential burdens of the pro-
gram?
• Can burdens be minimized? Are there alternative ap-
proaches?
• Is the program implemented fairly?
• How can the benefits and burdens of the program be
fairly balanced?
Childress and colleagues (2002) enumerate five consider-
ations to be weighed when analyzing the ethical dimen-
sions of public health action: effectiveness, proportional-
ity, necessity, least infringement and public justification
(Childress et al., 2002). Upshur (2002) has added to these
in his proposal of the following four principles to guide
the justification of public health intervention: the harm
principle; the principle of least restrictive or coercive
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means; the reciprocity principle; and the transparency
principle.
The seven emerging key principles that could consti-
tute a public health ethics framework are listed below
(Childress et al., 2002; Upshur, 2002):
• Transparency Principle : Any public health decision has
to be as clear and accountable as possible, as well as
free from political interference.
• Effectiveness Principle : Requires evidence of the effec-
tiveness of a management in improving public health,
if other moral considerations are to be infringed upon.
• Necessity Principle : No other method of achieving a
particular ‘end’ would have less conflict with other
moral considerations.
• Proportionality Principle : A positive balance should be
achieved between potential benefits of a public health
intervention and any adverse effects brought about
by a conflict with other moral considerations, such as
infringing upon individual human rights.
• Harm Principle : The only justification of restricting
the liberty of an individual/group is to prevent harm
to others.
• Reciprocity Principle : The state should provide ap-
propriate assistance to individuals to facilitate their
public responsibility to adhere to any Public Health
intervention, for example, treatment or quarantine.
• Least Restrictive Means Principle : Any less coercive
means must be tried first before it is justified to
implement more intrusive Public Health restrictions
on liberty.
The ideas presented above have not yet been extensively
debated for their strengths and limitations. How and
when they will be implemented and with what effects
will be determined by an ongoing debate that will foster
refined concepts and their application.
We suggest that where consideration of some balanc-
ing between individual rights and the common good is
required for the implementation of much needed, and
potentially very beneficial, public health interventions,
including research to provide the evidence for such inter-
ventions, a public health ethics approach supplementing
traditional ethical principles could facilitate ‘trade-offs’
that have a morally convincing rationale.
In this paper we illustrate how the application of the
principles of public health ethics may be used to moti-
vate the inclusion of adolescent women in HIV preven-
tion trials of experimental interventions such as vaccines
and microbicides, without neglect of the conventional
principles considered in human research. In addition
we propose an additional principle—the common good
principle—for consideration when public health is sig-
nificantly threatened.
• Common good principle—during a public health crisis
in which many lives are threatened, and only inade-
quate preventive measures are available, the common
good can be elevated above the good of individuals
for researching or implementing a potentially effec-
tive preventive method.
This principle should not be used as a stand-alone princi-
ple, but rather within the emerging framework of public
health ethics and without losing sight of the principles of
conventional research ethics.
It should be noted at this stage that the principles
of public health ethics listed above were initially formu-
lated with other situations in mind—for example dealing
with the ethical issues that arise in relation to containing
spread of infectious disease. They were not formulated
with public health research ethics dilemmas in mind.
However, HIV prevention research presents the poten-
tial for great public health benefits, so we consider it
appropriate to explore how these newly evolving princi-
ples may be applied in such a context. It should also be
noted that these are all prima facie principles and that




There are three distinct issues to be considered in rela-
tion to inclusion or exclusion of adolescent women in
microbicide trials:
• The need for data on the safety and effectiveness of mi-
crobicides in adolescents, as a potentially very effective
future public health tool.
• Traditional protection of vulnerable minors.
• Some other ethical considerations including recogni-
tion of the cognitive autonomy of adolescents.
At an anatomical level, cervixes of younger women are
not yet fully mature. The columnar epithelium of part of
the outer exposed part of the adolescent cervix has yet
to change to the more protective squamous epithelium,
making young women more susceptible to STDs. Up
to 80 per cent of teenagers will have less progesterone
within 4 years of menarche, as they have anovulatory
cycles (Global Campaign for Microbicides, 2005). This
difference in progesterone levels may have a significant
effect on the vagina’s local immune responses.
Necessity
The ‘Necessity’ principle demands that no other method
of achieving a particular ‘end’ (in this case protection
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from infection) would have less conflict with other moral
values.
It could be argued that rather than include adolescents
in microbicide trials more could be done to educate in-
dividuals, and promote condom use, but the reality is
that more than this is needed to curtail the pandemic as
sequential HIV/AIDS statistics show. An effective micro-
bicide would be a simple intervention that could help,
in particular as it promotes empowerment of women as
a good example of a public health intervention that also
promotes individual autonomy, and therefore adolescent
inclusion would be permitted under this principle.
Microbicide use is initiated by women in circum-
stances where they are aware of the risk of HIV infection
but are unable to get their male partner to use con-
doms. Microbicide use will enable women to take at least
some personal control of their HIV risk. In relationships
characterised by good partner communication, includ-
ing communication about HIV risk and risk reduction,
it becomes a matter of choice for women to use the mi-
crobicide. Given the substantial threat that HIV poses
to women’s survival the availability of a method that
they can initiate to reduce their HIV risk and enhance
survival cannot be underestimated. In the case of adoles-
cents, HIV-free survival in the teens will facilitate them
entering their twenties with greater social and cognitive
ability to negotiate HIV risk reduction.
Notwithstanding age differences in cohorts, we are
learning from completed microbicide and vaccine trials,
that safety data generated in Phase I and II trials are
not adequate predictors of longer term safety of product
with extended use as is the case with Phase III trials. In
the cases we are considering here, these girls are being
considered for participation in a Phase III trial, with the
presumption that Phase I and II trials have been carried
out only in adults.
A crucial point in defence of a decision to include
high-risk adolescents in microbicide trials is that it in-
creases the potential for such trials to show the efficacy of
this potentially important public health measure (Kock
et al., 2006). High-risk adolescents include those living
in countries where HIV is primarily sexually transmitted
and where the HIV prevalence and incidence rates are
high. This is the case for young women in sub-Saharan
Africa where HIV infection is synonymous with sexual
debut and HIV infection is 3–6-fold higher compared
to males in the same age range. It would be pointless to
study a preventative intervention, such as microbicides
in a low-risk population. Once efficacy has been demon-
strated it will then be necessary to show that microbicides
are effective outside of trial conditions and in the real-
world setting. Negative studies are also of value as long
as trial participants have not been put at any greater risk.
Taking these factors into account, Moscicki (Division
of Adolescent Medicine at the University of California,
San Francisco, as reported by the Global Campaign for
Microbicides) has expressed the view that the biologic
and behavioural differences between young female ado-
lescents and older women justify separate safety and ef-
fectiveness data on adolescents (Global Campaign for
Microbicides, 2005). This invokes the principles of ne-
cessity in including adolescents in microbicide trials, and
the potential effectiveness of the intervention.
Effectiveness
The ‘Effectiveness’ principle emphasizes the importance
of evidence. The problem is that we have a paucity of evi-
dence regarding the risks and benefits of microbicide use
in adults or adolescents. Indeed we may never know the
risks, if microbicides are not tested on the adolescent age
group. If the efficacy of a microbicide were to be shown
in a good trial, then obviously its use as a public health
intervention would not be contested, although effective-
ness studies in real-world situations would still need to
be conducted. However, here we are discussing adoles-
cent involvement in the trial when we lack the evidence
required for invoking this principle. Again, however, the
chicken-and-egg situation arises—we need a trial to es-
tablish the risks. The solution may be to involve teenagers
in Phase I and II trials with parental permission in the
hope that this may be sufficient to satisfy this principle.
However, as we are considering minors being exposed
to unknown risks, we acknowledge that there is indeed
difficulty in meeting the requirements of this principle.
Common Good
Few would disagree that a method of preventing HIV
infection among young women, that is effective in real-
world settings, would be a considerable advance in re-
ducing the impact of a pandemic that is causing major
loss of life in young people. Given the need for solidarity
in the face of common threats it seems entirely reasonable
to give a high priority to the principle of the common




Traditional protection of vulnerable minors has been
focused on avoiding research on them that could be
done on others, obtaining parental or other appropriate
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surrogate consent, and through obtaining assent from
minors. We demand parental consent for minors simply
because minors are thought to lack the full capacity to
understand everything that needs to be understood to
make an informed decision. It is not doubted that they
may know what they want, and that they can make a
decision. The pertinent question is whether or not such a
decision is an adequately informed and considered one. It
could be argued that some parents may make a worse de-
cision for a particular individual, but no system can ever
be fully foolproof. Parents in all societies are considered
to have responsibility for the best interests of their child
all their life, and so they are the obvious proxy decision
makers. It is often hard to agree with a decision if it is not
one that we ourselves would have made, but the whole
point of respecting an informed decision is that there is a
choice to be made and we should respect the decision of
a person empowered with enough information to make
the best decision for themselves. If we were all to make
the same choice then any decision-making process for
such a choice would be totally futile.
Much attention has been focused on the conduct of
HIV prevention trials to ensure that obtaining informed
consent is not merely procedural in terms of a signa-
ture obtained prior to study procedures being initiated.
Indeed, novel and innovative approaches have been de-
veloped to ensure that participation is informed and truly
voluntary. Efforts have also been promoted to ensure that
all participants are fully informed about randomisation
and uncertainty of product efficacy in addition to re-
ceiving adequate counselling on known methods of HIV
prevention (Global Campaign for Microbicides, 2005).
Comprehension assessments following enrolment con-
sent and prior to randomisation have become the norm
in HIV prevention trials.
These steps ensure the ‘consentee’s’ decision-making
capacity, i.e., their competence, and their comprehen-
sion, as well as an explicit declaration to participate or
refuse. These points are particularly relevant in relation
to considering adolescents’ autonomous consent or the
consent of parents. The problem faced in the cases under
consideration is that the adolescents wish to participate
either without parental consent, or in the absence of par-
ents to consent for her.
It is understandable for the first 16-year-old not to
want her parents to know that she is taking part in the
trial. First, she may not want them to know that she is
sexually active. Her parents may not approve, their re-
actions would be unpredictable, and anyway this should
not be relevant if personal choice (regardless of legal age)
has high moral value. We also have to consider the conse-
quences of requiring and obtaining parental permission
when adolescents are found to be HIV positive. Some
may argue that any infringement on the confidential-
ity entitled to an individual under these circumstances
is unethical, given that the stigma involved in assumed
HIV infection is the same as for actual HIV infection.
However, the harm principle would allow breaking con-
fidentiality if this would prevent harm to identifiable
others.
In the absence of parents it may be necessary to con-
sider the question of community consent, which may
involve the consent of a village chief or church leader.
Partner consent may also need to be considered in some
contexts. It is often the cultural norm in the developing
world to grant either initial or total authority for decision
making to the male in relationships. It seems paradoxical
to consider men’s involvement, much less their consent,
to test a product that could allow disempowered, and of-
ten scared, women to protect, and empower, themselves,
especially as many men refuse to use condoms, and levels
of domestic violence are often very high. This considera-
tion limits a female participant’s autonomy and it seems
common sense for it to be up to the female participants
to determine if and how their male partners are to be
involved. A full discussion of these matters, and of how
women could be empowered to refuse sex, is beyond the
scope of this essay, but these issues do need to be con-
sidered as they have some bearing (albeit small) on both
the cases we discuss.
It should be acknowledged that the success of any pos-
sible future for microbicides relies on their acceptability
to men. The same can be said for users’ adherence to
regular use. In South Africa, the principal worry for men
about microbicide use is that it may interfere with their
sexual pleasure. Some traditional laws would go so far as
to punish a woman, and probably readily force her not
to participate, if she is found by her partner to be using
‘something in her vagina’ without his knowledge (Global
Campaign for Microbicides, 2005: chapter 5, 24).
Harm
The standard way of talking about harm is to say that
the only justification for an intervention that limits in-
dividual liberties is that the intervention must prevent
harm to others. This is not directly applicable here as
allowing an adolescent to consent to participation is not
an infringement of liberty, unless it is viewed as inter-
fering with her liberty not to be an under-age research
subject. From the perspective of the common good prin-
ciple it can be argued that if an adolescent did not take
part in such a study, harm could be done to her sexual
partners and any children she may bear, or in the case of
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the second girl to those for whom she is now responsi-
ble. It would also allow the interpretation that reciprocal
freedom from harm (within consideration of the com-
mon good) would support participation of adolescents
in socially valuable research.
Some Other Ethical Considerations
Autonomy
It is probable that adolescents would want to take part in
microbicide and vaccine trials and obviously it is impor-
tant for any such potentially preventive measure to target
young people before their sexual debut. In support of this
contention we note that Jaspan et al. found that 79 per
cent of adolescents aged 11–19 years in a Xhosa-speaking
community near Cape Town were willing to participate
in a vaccine trial (Jaspan et al., 2006).
Recognition of Adolescent Cognitive Autonomy
Although cognitive, abstract thinking is developed in
mid-adolescence (14–16 years), the age range during
which such thinking is adequately developed is very wide.
We need to ask whether the cognitive abilities of the ma-
jority of adolescents may approximate those of young
adults, giving them the ability to understand the long-
term risks and benefits of any research. With the priority
many governments are placed on schooling in much of
the developing world, it is likely that many adolescents
may have had more formal education than many adult
participants in their countries, and with that, more train-
ing in reasoning and rational thinking. Both these points
are relevant to informed consent.
The cases we are considering here resemble the case
in which the notion of Gillick/Fraser competence was
explored (Wheeler, 2006). From this it can be argued
that if a minor can be shown to be mature enough to
understand the purpose of the proposed study and the
level of involvement requested, including benefits and
risks, then he/she should be able to consent. However,
this may need to be determined by two professionals
(as for Gillick/Fraser competence) who are independent
from the researchers in order to avoid bias and to provide
as objective a judgement as possible.
It is of interest to note that in South Africa adoles-
cents, 16 years and over, can legally consent to sex, but
are not permitted the autonomy to legally consent to par-
ticipation in a trial designed to help protect them dur-
ing sex. The Children’s Bill in South Africa (June 2005)
states that young people can have access to contracep-
tion without parental consent from the age of 12 (Kock
et al., 2006). The new Health Act states that children as
young as 12 can consent to medical procedures if they
can be shown to understand fully the process and con-
sequences. Yet 16-year-olds cannot legally consent for
themselves to participate in trials evaluating preventive
measures. Discussions held with the Medicines Control
Council (MCC) and Ethics Committees in South Africa
has led to a better appreciation by IRBs of HIV risk faced
by adolescent girls. Indeed one of the co-authors (Q.
A. K.) has had the experience of MCC and UKZN Re-
search Ethics Committees requesting an explanation for
why 16- and 17-year-old women were not included in a
microbicide trial being conducted by her.
In a study of the informed consent process, as viewed
by children, it was found during post-test counselling that
concrete elements of research, such as the duration of the
study and benefits to themselves, were understood the
best. However, participants had difficulty understanding
more abstract issues such as the purpose of study, benefits
to others and alternative treatments. While the study
included children who had yet to reach the age for mature
abstract thinking the authors also attributed the lack of
understanding to inability to place their participation in
context because of lack of life experience (Susman et al.,
1992).
Some Implications of Adolescent Consent
Potential repercussions of excluding parental consent in-
clude the possibility that if parents were to find out that
some teenagers in the community were involved in such
a trial and suspect that their children are involved, re-
searchers could be alienated from communities and lose
support for the study, with consequent loss of many bene-
fits that could accrue to communities from the research.
In order to avoid this, consideration could be given to
asking the community to give permission for teenagers
to participate and then asking the teenagers themselves
to give personal consent without having to divulge their
decision. However, even this may lead to pressure from
parents or friends to reveal who is involved, and partici-
pation may have repercussions for the youth.
There is concern too about infringing upon the rights
of parents as in addition to their natural responsibility
they also have a legal responsibility to care for the welfare
of their children. However, precedents have been set re-
garding bypassing of parents’ wishes in situations where
public health considerations are overriding.
Singh et al. writing about the importance of enrolling
adolescents in trials such as these, note that The Human
Sciences Research Council reports an almost doubling of
South African households that are headed by children,
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or consisting only of children, in 2002–2005 (Singh et al.,
2006). In 2005, among children aged 12–18 years, 2.6 per
cent (180,433) identified themselves as head of house-
holds. Among orphans, 2.8 per cent (213,859) identi-
fied themselves as being head of households, and almost
65 per cent of orphans live in community/family care or
child-headed households (Singh et al., 2006). The girl in
Case Study 2 is thus far from an isolated case and this
position should be acknowledged for legal and medi-
cal purposes that would hopefully include the ability to
participate in trials.
It is notable too that many adolescents who attend
prenatal and family planning clinics do not live with
their parents. They either live alone because their par-
ents are deceased, live/work in a distant area or because
they are in the care of members of the community, usu-
ally relatives (with most of these surrogate caregivers
not formally appointed or recognised as the child’s legal
guardian) (Singh et al., 2006). Under these circumstance
it seems to be most logical for the adolescent themselves
to give consent if they can be shown to have the requi-
site understanding. It could be argued that the very fact
that they are attending either a family planning clinic
or antenatal clinic identifies them as probable mature
minors.
It is perhaps easier to argue for the inclusion of the
second adolescent in a trial. However, it would be neces-
sary to indicate whether it would be fair to allow her to
participate and not the other adolescent? Her situation
is very unfortunate but does this warrant her to be sud-
denly assigned ‘adult’ status. We are told that she has the
responsibility of an ‘adult’ position, but we have no idea
how she is coping with such responsibility ahead of her
years. Her position now as ‘head of the household’ does
not necessarily make her capable of making an informed
choice. She may have greater experience of some aspects
of life than the first girl, but does that necessarily make
her better equipped for such a decision?
Conversely, if the situation remains that adolescents
can only participate, with parental consent, then, this
would also be unfair, as it would exclude the second girl
because of her situation, as she has no parents to consent
for her. One could also argue, hypothetically speaking,
that she may be at more risk. The financial pressures on
this girl could be so heightened that she is more ready
to take part in ‘transactional sex’ with older men, both
factors putting her at an increased risk.
A further issue is that in many countries sexual
intercourse, even if consensual, below certain ages is
considered rape and there may be legal obligations of
researchers to report rape. However, there have been sev-
eral precedents where research has been conducted in
vulnerable populations in which sexual activity, injected
drug use and same-sex relationships are considered il-
legal, without obligation to report these individuals to
law enforcing agencies on the grounds that the relation-
ship between research participants and the study team is a
confidential one and needs to be respected. The common
good principle could also be invoked here to support
research designed to benefit whole groups. Adolescent
and adult women participants who report sexual, verbal,
or physical abuse are counselled about their rights, in-
formed about what legal recourse is open to them and
directed to sources of support in the community that
they can access.
In the case of sexually active adolescents it is not for
the researcher to pass moral or other judgement on the
adolescent being sexually active. The researchers’ respon-
sibility in undertaking such research is to minimize harm
including risk of acquiring HIV infection. The reality is
that despite legal restrictions many adolescent girls and
boys are sexually active and not all of the coital activity is
coerced but is in fact consensual.
Beneficence
Well-intended advantages of participation in microbicide
trials include:
• trial-provided condoms and condom counselling in
the participant’s own language—an important public
health advantage for everyone
• decreased risk of HIV infection for all regardless of
which arm of the trial to which they are randomised
• material benefits, which include reimbursement for
transport time and childcare, and food at the clinic
• early detection and treatment for STDs, discovered
during the trial
• HIV counselling and referral for both the participant
and their partners to suitable care and/or referral for
any pregnancies during the trial.
While these may be viewed as inducements to participate,
it could also be the case that they would not be seen in
this light in the face of what is probably minimal risk and
potentially significant benefits.
There are also many collective benefits (common
good) that should ensue for the local communities when
a trial is conducted, some of which are immediate and
tangible while others manifest later:
• health services are improved in the locale of the trial in
order for trial ‘managers’ to maintain an appropriate
standard of care—whatever that is decided to be in a
particular context (Shapiro and Benatar, 2005)1
• enhanced access to tests and information and training
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• fewer HIV seroconversions in women in the general
community because of the decreased risk brought
about by the efforts offered as part of the trial (Global
Campaign for Microbicides, 2005).
• access to antiretroviral treatment in the future
• overall benefit for a community that feels it is ‘doing
its bit’ for the pandemic—so generating feelings of
self-worth and hence community well being.
Justice
Within bioethics debates the principles of autonomy (re-
spect for persons) and beneficence are now increasingly
linked to consideration of the principle of justice. Ex-
pansion of microbicide research to include adolescents
with their personal consent would be supported by the
principle of justice, as such inclusion would facilitate
the equitable spread of the benefits of research and thus
hopefully, improve health for many – an important aim
for public health interventions.
However, it is the burdens of research that are prob-
lematic here. It could be argued simply that minors, in-
cluding adolescents, are a vulnerable group, and as such
should not be party to more burdens/risks than occur
simply as a course of nature. This would justify pro-
viding them with benefits while not requiring them to
share in the risks. This is in general the approach we take
with children on the assumption that when they become
adults they will then bear some of the burdens required
to assist new generations of children. Such an approach
may, however, delay the acquisition of data required to
advance the health of adolescents
Debates on justice in research in the 1980s provide a
precedent. At that time the idea that women were vulner-
able and not allowed to take part in research, was replaced
with the argument that ethically they had to be included
so that they could enjoy the benefits of research, as well
as share in the risks, especially when the research was
particularly relevant to their health (Epstein, 2007). We
suggest that the same could apply to adolescents under
the conditions we have described here.
In order to minimise the risks involved for adolescents,
a good compromise would be to first conduct Phase I and
II trials involving willing adolescents who have parental
consent. Then, when more information is available about
their safety and communities are more comfortable with
the knowledge of these, Phase III trials could be set up
on the basis of community collective consent followed
by individual consent given by the adolescent if she can
be shown to understand the process and consequences
adequately, and this is agreed on by two objective pro-
fessionals. This would add support for the argument for
participation under the ‘Proportionality’ principle.
Proportionality
The ‘Proportionality’ principle requires that there be a
positive balance between potential benefits of a public
health intervention and the adverse effects of infring-
ing upon an individual’s human rights. This is especially
relevant to this discussion. It also must be expanded to
encompass a broader balance of benefits and risks, be-
cause any public health intervention must simply have
greater benefits then risks. We have discussed the ben-
efits for participation for both the adolescent and the
community, and we suggest that it is also necessary to
emphasise benefits to the host country and therefore to
public health in its broadest sense.
Potential harms include adverse physical effects of mi-
crobicide, stigma, emotional stress consequent upon par-
ticipation or outcomes of the trial and the adverse effects
of an adolescent participating without parental consent.
Consideration of this principle also requires balancing
infringement of parental rights to protect their children,
against the public health benefits of adolescent partici-
pation. However, it is also important to consider the in-
dividual benefits to the adolescent, including respect for
her autonomy and decision-making capacity. Such in-
dividual benefits do after all contribute to public health
benefits, and need to be considered in the proportionality
equation.
Transparency
Trials involving Tenofovir highlighted the importance of
the ‘Transparency’ principle in building community trust
(Anonymous, 2005). The crucial element here is that in
all trials there should be as much transparency as possible
and promotion of as much understanding as possible at
community level, to ensure open accountability, legiti-
mate participation and minimal risks. In a microbicide
trial involving adolescents, the above-mentioned Phase I
and II trials would be part of the process of promoting
transparency
Reciprocity
This principle requires that individuals who contribute
to the public good at the expense of their own wishes or
rights (or without parental consent) should receive the
support required from the state to enable them to make
these sacrifices more easily. In relation to microbicide
trials this principle demands that future responsibilities
be clarified so that provision of care when needed is
met. Adolescent participation would therefore require
consideration of post-trial access. Unless such issues are
dealt with proactively, ethical quandaries could delay or
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derail a generation of future trials (Global Campaign for
Microbicides, 2005).
Obligations to adolescents would be the same as to
adults, with recognition that it is increasingly accepted
that becoming HIV positive during a trial imposes the
obligation on researchers to ensure ARV treatment when
this may be required. The difficulty lies in meeting this
obligation when the need may only arise a decade or
more after the trial has ended
With this in mind, several operational issues would
need to be addressed—namely, the mobility of the ado-
lescent population and subsequent participant tracking
difficulties; future access to, and ‘marketing’ of, microbi-
cides for vulnerable populations; both provision of and
fiscal considerations of future access to ARVs for those
participants who contract HIV during the trial and, fi-
nally, how continued access to microbicides (if deemed
effective) would be maintained, both logistically and fi-
nancially. It is difficult to properly consider a minor tak-
ing a personal risk when the answers to these questions
are not available. If we were to consider that adolescents
should participate, especially under the justification of
advancing public health, then the risk should be as small
as possible—which will only be the case, if the above
questions are answered—or the public health advantages
so great that these become of major significance.
Some Cultural Considerations
Molyneux et al. emphasise that, in such discussions
of ethics there is an underlying controversy regarding
whether conceptions of human rights and models of eth-
ical reasoning are absolute in their application to com-
munities and countries that differ enormously in socioe-
conomics, culture and politics (Molyneux et al., 2005).
They challenge the notion of individual consent as far as
relevance and priority go and explain this by referring to
the low levels of formal education; poor access to good
quality biomedical services; different values, priorities
and understandings of health and illness; the roles of the
community, chiefs, sangomas or alike, elders, men and
women and, lastly, the problems of the actual physical act
of reading and signing the consent form. They acknowl-
edge the importance of community-level consultation
and permission, and alternative methods of communi-
cating other than reading and writing. From their work in
Kenyan communities they unequivocally observed that
for children aged less then 18 years, parents were asked
(and probably should be in that society), and that in gen-
eral it was the father who had the stated decision-making
authority. If the father was absent, or could not give per-
mission, then the mother, or other males or elders of the
household, could do so. We cannot necessarily extrapo-
late this to all communities but it does give us an idea
that what we argue for may not necessarily be the same in
communities far removed from our own. As Upshur says,
‘. . . populations are constituted by diverse communities
of heterogeneous beliefs and practices . . . these may at
times conflict’ (Upshur, 2002).
A Balanced Decision
The value of respect for persons and informed consent
would make it incumbent on researchers to do every-
thing possible to ensure that the moral requirements for
informed consent are met even if the legal (age) require-
ments cannot be met. Considerations of inclusion as
justice would favour adolescent participation. The pub-
lic health necessity for the knowledge that could be ac-
quired from including adolescents in microbicide tri-
als, the relatively minimal harm that would be done to
them, the benefits that would flow to adolescents as a
group and the reciprocity value associated with guaran-
teed post-trial access would all be in favour of including
adolescents in the microbicide trials. We conclude that
there is adequate moral justification for doing so utilising
both conventional concepts of research ethics and newly
formulated principles of public health ethics.
Conclusions
The two cases we discuss raise a very realistic debate
on how to consider public health goals when these may
infringe on individual rights. We have noted that there
are both benefits and disadvantages of the permissive
inclusion of adolescents in a microbicide trial. The public
health debate centres on the balance between the rights
of the individual to be treated equally and fairly, and,
the need to achieve the greatest potential public health
benefits (Benatar, 2006). An emphasis on Public Health
is far from misplaced and of ever-increasing importance
as the growing HIV/AIDS pandemic so clearly illustrates.
The health of whole populations is, in part, made up of
the sum of every individual’s health and therefore indi-
vidual health does have a bearing on population health.
However, public health is more than just an aggregate of
the health of many individuals. Public health consider-
ations require that we also address the socio-economic
and cultural foundations of health, and their influence
on inequalities (Benatar, 1998; Birn, 2005). Public health
aims to protect those who need protection, and hence
has a high regard for the human rights that at times it
has to infringe.
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There is also a need to challenge conventional public
thinking and complacency. Nixon and colleagues refer to
the magnitude of the response that was mounted against
SARS, a global infectious disease that predominantly af-
fected the rich world, and compared this to the inade-
quate response that is being mounted against infectious
disease such as HIV and TB, which affect the developing
world predominantly but kill over 10,000 times as many
people every day than SARS did during the 2002–2003
epidemic (Nixon et al., 2005). When we think of public
health we often think of extreme, paternalistic, interven-
tion measures. The recent SARS problem in Canada led
to quarantining—a huge infringement of individual lib-
erties for the good of the public (Singer et al., 2003).
Such interventions could not be condoned for HIV for
many reasons. However, it is now necessary to consider
ethical justification for public health measures that could
significantly impact on this tragic HIV/AIDS pandemic.
An effective microbicide could not only make a sig-
nificant contribution to public health, but it would also
promote individual health. This is an example of not
relying on paternalism but rather on empowering indi-
viduals to be autonomous and making their own choices.
It stands as an excellent example that one good need not
negate another good and that there is a symbiotic re-
lationship within which promotion of either individual
health or public health can lead to the promotion of the
other.
As consideration of adolescent participation in micro-
bicide trials will inevitably be associated with potential
adverse effects, decisions to involve them will be con-
troversial. Their inclusion can be defended using princi-
ples of public health ethics combined with conventional
individual-based ethical reasoning.
To be ethical and responsible requires consideration
of the public health effects of our actions. This applies
especially to health professionals, all of whom face lim-
itation on use of resources, although admittedly to very
different extents in different countries.
Any possible future effective microbicide would be
a highly valued public health tool, and therefore there
is a need to support microbicide trials with inclu-
sion of those groups that are at the highest risk—here,
adolescents—who also stand to be the most significant
beneficiaries. Participation in such trials is a perfect ex-
ample of maximising public health at many levels—the
possibility of finding an effective HIV preventative mea-
sure, producing community health benefits as well as
benefits for the host country and participants themselves.
To achieve these goals requires a ‘shift in mindset away
from strong individualism towards respect for individ-
uals within a context of a sense of duty towards a com-
munity’ (Benatar et al., 2003). Generally, public health
thinking is thought to be opposed to the promotion of in-
dividual autonomy over health, but we have argued that
each can help promote the other—we need to respect
individuals, but in the context that every individual is
part of a community or communities—a simple fact that
itself helps to shape that individual’s life, health and way
of thinking.
It is also relevant to note in conclusion that a prereq-
uisite for successful HIV prevention research is greater
understanding of the meaning and control of sexual ac-
tivity in different cultures. Without such understanding
efforts to study or impose ideas about protection are
likely to be less effective. Much work remains to be done
to develop and implement effective preventive measures.
Note
1. The subject of the appropriate standard of care is
again a much discussed subject that is beyond the
breadth of this discussion. However, consideration of
this dilemma is relevant for all participants and es-
pecially when considering the inclusion of minors in
these trials.
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